Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT02792725 Approved for marketing - Clinical trials for Metastatic Breast Cancer

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT01240421 Approved for marketing - Clinical trials for Metastatic Breast Cancer

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Start date: March 2011
Phase: N/A
Study type: Expanded Access

This expanded access program is an open-label, multi-center study, which will consist of a PreTreatment Phase and a Treatment Phase. Patients with locally advanced or metastatic breast cancer who fulfill the eligibility criteria will be treated. The program will continue in each country until eribulin is approved, reimbursed and launched in that country, or termination of the program by the Sponsor.